|
Basic Characteristics of Mutations
|
|
Mutation Site
|
G142D |
|
Mutation Site Sentence
|
However, it had an acquired G142D mutation and a larger deletion of 3-amino-acids at position 143-145. |
|
Mutation Level
|
Amino acid level |
|
Mutation Type
|
Nonsynonymous substitution |
|
Gene/Protein/Region
|
|
|
Standardized Encoding Gene
|
|
|
Genotype/Subtype
|
20A |
|
Viral Reference
|
MN908947.3
|
|
Functional Impact and Mechanisms
|
|
Disease
|
COVID-19
|
|
Immune
|
- |
|
Target Gene
|
-
|
|
Clinical and Epidemiological Correlations
|
|
Clinical Information
|
- |
|
Treatment
|
- |
|
Location
|
- |
|
Literature Information
|
|
PMID
|
35150193
|
|
Title
|
Severe relapse of SARS-CoV-2 infection in a kidney transplant recipient with negative nasopharyngeal SARS-CoV-2 RT-PCR after rituximab
|
|
Author
|
Morel A,Imbeaud S,Scemla A,Pere H,Fourgeaud J,Amrouche L,Robillard N,Planas D,Puech J,Simon S,Lanternier F,Belec L,Zuber J,Schwartz O,Anglicheau D,Chavarot N,Veyer D
|
|
Journal
|
American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
|
|
Journal Info
|
2022 Aug;22(8):2099-2103
|
|
Abstract
|
Immunocompromised patients may experience prolonged viral shedding after their initial SARS-CoV-2 infection, however, symptomatic relapses after remission currently remain rare. We herein describe a severe COVID-19 relapse case of a kidney transplant recipient (KTR) following rituximab therapy, 3 months after a moderate COVID-19 infection, despite viral clearance after recovery of the first episode. During the clinical relapse, the diagnosis was established on a broncho-alveolar lavage specimen (BAL) by RT-PCR. The infectivity of the BAL sample was confirmed on a cell culture assay. Whole genome sequencing confirmed the presence of an identical stain (Clade 20A). However, it had an acquired G142D mutation and a larger deletion of 3-amino-acids at position 143-145. These mutations located within the N-terminal domain are suggested to play a role in viral entry. The diagnosis of a COVID-19 relapse should be considered in the setting of unexplained persistent fever and/or respiratory symptoms in KTRs (especially for those after rituximab therapy), even in patients with previous negative naso-pharyngeal SARS-CoV-2 PCR.
|
|
Sequence Data
|
-
|
|
|